Lucid Diagnostics Inc.

• US
• Lucid Diagnostics Inc.
• Health-Care

LUCD

Offering Team

Pre-IPO Investors

Deal Highlights

We are a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC).

We believe that our lead products, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell Collection Device in a brief noninvasive office procedure, constitute the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent EAC deaths, through early detection of esophageal precancer and cancer in at-risk GERD patients. We believe EsoGuard could have as great an impact in preventing EAC deaths as widespread Pap test screening has had in preventing cervical cancer deaths.

We were incorporated in Delaware on May 8, 2018, as a wholly owned subsidiary of our parent company, PAVmed Inc. (Nasdaq: PAVM), a highly differentiated, multi-product, commercial-stage medical technology company. On May 12, 2018, we entered into a license with Case Western Reserve University (CWRU), which granted us an exclusive worldwide license to the intellectual property rights of the technologies underlying EsoGuard and EsoCheck, for use in the detection of changes in the esophagus. In addition, the three CWRU physician inventors each entered into consulting agreements with us to continue to support the development of the licensed technologies. Since our inception we have been managed pursuant to a management services agreement with PAVmed and have financed our operations to date through working capital advances from PAVmed.
less

We are a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). We believe that our lead products, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell Collection D More

Deal Tracker

Stock Price